Sutro Biopharma, Inc.

Equities

STRO

US8693671021

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4.93 USD +17.94% Intraday chart for Sutro Biopharma, Inc. +45.00% +14.92%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup DJ
Wedbush Adjusts Sutro Biopharma's Price Target to $8 From $12, Maintains Outperform Rating MT
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Sutro Biopharma, Inc. - Special Call
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC CI
Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from NASDAQ Biotechnology Index CI
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023 CI
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma; Sutro Shares Jump Premarket MT
Vaxcyte Exercises Option for Manufacturing Rights Agreement With Sutro Biopharma MT
Vaxcyte, Inc. Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control over Manufacturing and Development of Cell-Free Extract for Its Vaccine Candidates CI
Sutro Biopharma Promotes Jane Chung to Newly Created Position of COO MT
Sutro Biopharma, Inc Appoints Jane Chung as President and Chief Operating Officer CI
Piper Sandler Adjusts Price Target on Sutro Biopharma to $12 From $18, Maintains Overweight Rating MT
Earnings Flash (STRO) SUTRO BIOPHARMA Reports Q3 Revenue $16.9M MT
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sutro Biopharma Says Endometrial Cancer Therapy Showed 'Encouraging Preliminary Anti-Tumor Activity' MT
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Endometrial Cancers At ESMO 2023 CI
Oppenheimer Initiates Coverage on Sutro Biopharma With Outperform Rating, $10 Price Target MT
Sutro Biopharma, Inc. Appoints Hans Peter Gerber as Chief Scientific Officer CI
Transcript : Sutro Biopharma, Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-06-2023 08:00 AM
Wedbush Cuts Sutro Biopharma's PT to $12 From $20, Pushes Back Estimated Launch of STRO-002, Adjusts Capital Raise Assumptions; Keeps Outperform Rating MT
Earnings Flash (STRO) SUTRO BIOPHARMA Posts Q2 Revenue $10.4M MT
Sutro Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sutro Biopharma, Blackstone Sign Royalty Financing Agreement MT
Sutro Biopharma and Blackstone Announces Royalty Financing Collaboration CI
Chart Sutro Biopharma, Inc.
More charts
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It provides two wholly owned ADCs in the clinic, namely luveltamab tazevibulin (STRO-002 or luvelta) and STRO-001. STRO-002 is an ADC directed against folate receptor-alpha (FolRa) for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. STRO-001 is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma (NHL). Its preclinical product candidate, STRO-003, is a single homogeneous ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), developed for the treatment of solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.93 USD
Average target price
13.78 USD
Spread / Average Target
+179.47%
Consensus
  1. Stock
  2. Equities
  3. Stock Sutro Biopharma, Inc. - Nasdaq
  4. News Sutro Biopharma, Inc.
  5. Sutro Biopharma Provides Update on Cancer Tumor Treatment Technology